Rifamail 150 Capsule contains Rifampicin 150mg, a first-line anti-tuberculosis agent used in the treatment of TB and other bacterial infections. It helps in eradicating Mycobacterium tuberculosis and preventing disease progression.
Rifampicin works by inhibiting bacterial RNA polymerase, thereby suppressing bacterial protein synthesis and promoting rapid microbial clearance. Its effectiveness in combination therapy makes it a cornerstone in TB treatment protocols.
Capsule formulation ensures accurate dosing, stable bioavailability, and convenient administration, enhancing patient adherence. Due to its critical role in TB management, Rifamail 150 Capsule maintains consistent demand in hospitals, clinics, and government health programs.
Adding Rifamail 150 Capsule to your anti-tuberculosis and anti-infective portfolio strengthens your product range with a high-rotation, trusted molecule. Its prescriber confidence, institutional use, and export potential make it ideal for PCD pharma companies, distributors, and third-party manufacturing partners.